來凱醫藥-B(02105.HK)擬配售合共1763.6萬股 總籌2.36億港元
格隆匯11月21日丨來凱醫藥-B(02105.HK)發佈公吿,2024年11月21日,公司與獨家配售代理(即中信證券)訂立配售協議,據此,公司已有條件同意透過獨家配售代理以每股配售股份13.36港元的價格向不少於六名承配人配售合共1763.6萬股配售股份。
配售股份將佔本公吿日期公司現有已發行股本約4.52%及緊隨完成後經擴大已發行股本約4.33%。配售股份將根據一般授權配發及發行,無需取得任何的股東批准。假設所有1763.6萬股配售股份獲悉數認購,於完成後,所得款項總額將約為2.36億港元,配售事項所得款項(扣除配售佣金和其他相關花銷和專業費用後)淨額估計為2.30億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.